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Regardless of the type of arterial reconstruction, luminal narrowing (stenosis or restenosis) develops in approximately one
third of the vessels. In the past, the focus of research has been on the mechanisms of stenosis (intimal hyperplasia,
pathologic remodeling) and pharmacologic approaches to prevention. An alternative approach is to induce intimal
atrophy after luminal narrowing has developed, thus limiting treatment to only those patients that develop a problem.
This approach to treat established disease by reducing wall mass through induction of cell death and extracellular matrix
removal would be particularly useful for treating stenosis in synthetic bypass grafts or stented vessels, in which intimal
hyperplasia is the primary mechanism of stenosis. This approach may be applicable as well to other vascular proliferative
disorders, such as pulmonary hypertension and chronic transplant arteriopathy. Proof of principle has been shown in
experiments with antibodies to platelet-derived growth factor (PDGF) receptors that cause neointimal regression in
baboon polytetrafluoroethylene (PTFE) grafts and with angiotensin-converting enzyme inhibitors that induce medial
atrophy in hypertensive arteries. Possible molecular targets could include PDGF receptors, A20, and BMP4. Further
studies are needed to determine the utility of such a therapeutic approach to vascular disease. ( J Vasc Surg 2008;47:
662-70.)Arterial occlusive diseases are treated by various open
and endovascular approaches including bypass graft, end-
arterectomy, atherectomy, balloon angioplasty, and stent
angioplasty. Regardless of the type of intervention, stenosis
or restenosis develops in a significant number of patients,
often leading to limb loss or death.1,2
Research on restenosis has focused on the biological
mechanisms of vascular hyperplasia caused by vascular in-
jury and on pharmacological strategies to prevent hyperpla-
sia. Drug eluting stents are a successful application of these
strategies, although late stent thrombosis may be a result of
inhibiting endothelial cell healing as well as smooth muscle
cell (SMC) proliferation.3 An alternative approach might
be to induce intimal atrophy after restenosis has developed.
This approach would be particularly useful for treating
stenotic and restenotic disease in synthetic bypass grafts or
stented vessels, since restenosis in these rigid vessels only
involves intimal hyperplasia and not vessel remodeling.
Furthermore, it would permit the surgeons to treat only the
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662subset of patients with restenosis. Since patients with reste-
nosis often have symptoms (worsening claudication or an-
gina), they are easily identified. This strategy might also be
applied to pulmonary arterial hypertension and chronic
transplant arteriopathy, which share the pathophysiologic
features of increased arterial wall mass and luminal narrow-
ing. In this review, we will summarize the evidence that
vascular hyperplasia is reversible and that a strategy to
reduce wall mass through inhibition of proliferation and
induction of cell death and extracellular matrix loss could
be applied to many vascular disorders. As background, we
will first briefly review mechanisms of vascular hyperplasia
and hypertrophy.
MECHANISMS OF VASCULAR HYPERPLASIA
AND HYPERTROPHY
The vascular response to injury has been studied in
animal models for four decades, and the cellular and mo-
lecular mechanisms of intimal hyperplasia and medial hy-
pertrophy are understood in some detail.4,5 For example,
mechanical or hemodynamic endothelial injury (eg, after
angioplasty and stent or vein graft placement) may expose
the subendothelial matrix and induce platelet adhesion,
aggregation, and activation. Activated platelets release var-
ious cytokines, chemokines, and growth factors, which
initiate SMC proliferation, leukocyte recruitment, and ac-
tivation of the coagulation cascade. Substances released or
activated after injury include platelet-derived growth factor
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(IL)-1, IL-6, IL-8, thrombin, adenosine diphosphate, and
thromboxane A2. The maximal intimal response requires
medial damage, as well as endothelial cell injury.6 Indeed,
SMCs around the area of injury begin to undergo apoptosis
within 1 hour of injury, and while blockade of apoptosis
after endothelial and medial injury inhibits intimal hyper-
plasia,7 SMC apoptosis without endothelial injury does not
lead to intimal hyperplasia.8
Rat medial SMCs begin to proliferate within 48 hours.9
Fibroblast growth factor (FGF)-2 plays a major role in this
initial proliferative event. It is released from damaged en-
dothelial and SMCs, and, while antibody blockade prevents
the proliferation of SMC in the rat carotid media by
80%,10 it has no effect on subsequent cell proliferation in
the intima.11 In contrast to the injured rat carotid in which
PDGF plays a minor role in medial SMC proliferation,12 a
blocking antibody to the PDGF receptor (PDGFR) 
inhibits medial SMC proliferation 90% in the baboon
saphenous artery.13 Other factors such as insulin-like
growth factor (IGF)-114,15, thrombin16, TGF- ,17 to-
gether with cytokines IL-118 and IL-6, all contribute to
SMC proliferation. A host of inhibitory factors also mod-
erate the proliferative response to injury, such as adiponec-
tin,19 heparan sulfate proteoglycans (eg, perlecan20; synde-
can-121), interleukin 1022, adrenomedullin,23 and
somatostatin.24 In addition, high blood flow inhibits inti-
mal hyperplasia after arterial injury.25,26
After 4 days, medial SMC proliferation reaches a peak
in both rodent and primate models of injury, and SMCs
begin to migrate to the intima. PDGF clearly plays a major
stimulatory role for SMC migration in both rodents27 and
primates.28 It is released from platelets and is also upregu-
lated in the vessel wall29 in endothelial cells, SMCs, and
macrophages. Insulin30, tissue factor,31 and FGF232 also
contribute to SMC migration in vivo.
Intimal SMCs are derived primarily from the media,
but they may also be derived from adventitial myofibro-
blasts, pericytes associated with infiltrating microvessels,
and circulating progenitor cells.33,34 Intimal SMCs prolif-
erate for up to 2 weeks and begin to express major extra-
cellular matrix (ECM) genes, such as elastin and collagen I,
by approximately 7 days after injury.35 The intima grows as
elastin, collagen, glycoproteins, and proteoglycans are syn-
thesized and secreted. Between 1 and 3 months, a steady
state is reached at which time the intima is 20% cells and
80% ECM.35
The response of previously injured vessels to reinjury
has also been investigated. Koyama and Reidy36,37 ob-
served intimal and medial SMC proliferation in response to
a second balloon injury to the rat carotid, but found that
the intimal thickening was entirely from increased ECM
synthesis not SMCs. Hanke et al38 performed balloon
injury to the rabbit carotid previously injured by electrical
stimulation. They found that proliferation continued at low
but significant rates up to 3 weeks and that the number of
intimal SMCs nearly doubled.VASCULAR ATROPHY IN NORMAL
DEVELOPMENT
Vessel regression is an essential aspect of the develop-
ment of the vascular system, which includes the processes of
vasculogenesis (de novo formation of blood vessels) and
angiogenesis (budding of new vessels from preexisting ves-
sels).39,40 Regression occurs during development after for-
mation of a primary plexus of capillary-like vessels. In
addition, after birth, there is regression of the infrarenal
aorta where blood flow decreases dramatically, leading to
apoptosis and reduction of vessel diameter.41,42 In addi-
tion, there is a postnatal loss of a network of vessels in the
vitreous and around the lens of the eye. This latter vessel
loss depends on macrophage-induced endothelial cell
death.43 These processes are orchestrated by physical
forces, such as blood flow, as well as various stimulators and
inhibitors whose expression is tightly regulated both in a
temporal and spatial manner44 and which are reinitiated in
vascular disease in adults.45
Regression is an inherent component of any angiogenic
program.40 For new vessels to bud off, stable quiescent
vessels must first be destabilized. This process involves the
loss of surrounding pericytes. At this stage, the vessel can
either form a new vessel or regress, a process controlled by
relative activities of PI3 kinase and PLC.46 The presence
or absence of growth factors (eg, vascular endothelial
growth factor) and other angiomodulators (eg, endosta-
tin), which can be controlled by proteinases like cathep-
sins,47 dictate the fate of the destabilized vessel.
While induction of microvessel regression may be a
therapeutic strategy in many disorders associated with ab-
normal or excessive angiogenesis, such as cancer, psoriasis,
arthritis, retinopathy, obesity, and atherosclerosis,48 this
antiangiogenic strategy may not be applicable to larger
vessels. Nevertheless, it may be possible to induce atrophy
in large diseased arteries by various means described in the
next section of this review.
ANIMAL MODELS OF VASCULAR ATROPHY
High blood flow-induced intimal atrophy. In nor-
mal arteries, an increase in blood flow causes acute vasodi-
lation, a process that is dependent on endothelial release of
nitric oxide (NO). Chronic adaptation to increased flow is
also dependent on the endothelium.41 However, because a
rigid vessel, such as an artificial graft or calcified artery,
cannot dilate, the only way to normalize shear stress is to
reduce wall mass. We have investigated this possible mech-
anism of adaptation to increased blood flow. We have used
a polytetrafluoroethylene (PTFE) graft model in baboons,
in which bilateral PTFE (internodal distance 60 um, inter-
nal diameter 4 mm) aorto-iliac bypass grafts are allowed to
heal for 2 months. Unlike the reinforced 30-um internodal
distance PTFE grafts used clinically, these grafts uniformly
heal by the transmural ingrowth of microvessels through
the interstices of the PTFE. Complete endothelialization is
achieved by 2 weeks, and maximal, evenly distributed neo-
intimal thickening along the graft is complete by 2
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by the creation of a distal femoral arteriovenous fistula, the
neointima regresses markedly in the graft, but there is no
regression in the normal, adjacent iliac artery.50,51 It ap-
pears that vessels attempt to maintain shear stress at a
constant level between 5 and 25 dynes/cm2 by altering
luminal area. The downstream iliac artery, which does not
undergo atrophy, increases both overall and lumenal area in
response to increased flowwithout any change in wall mass.
The sequence of events leading to neointimal loss is shown
in Fig 1.
Neointimal SMC death increases and SMC prolifera-
tion declines by 1 day after fistula placement.52 There is also
evidence of ECM degradation beginning at 4 days associ-
ated with a proportional loss of cells. There is a particular
loss of the ECM proteoglycan versican.53,54 This is signif-
icant because the sulfate groups of the chondroitin sulfate
(CS) glycosaminoglycan chains of the GAG domain of
versican bind water. Thus, early collapse of the neointima
could be caused by glycosaminoglycan degradation and
loss of water.
The mechanism of flow-mediated regression is not
known. An interesting aspect of this baboon model is that,
while there is a continuous endothelial layer, it is dividing at
a much higher rate than in normal vessels. In baboons as
well as humans, SMCs do not accumulate in grafts unless
there is an endothelial layer and restenotic lesions usually
are endothelialized. The requirement for endothelium in
intimal regression has not been tested. However, while
increased blood flow clearly inhibits neointimal hyper-
plasia in the absence of endothelium in rat arterial injury
and graft models,26,25 and there are unknown endothelium-
independent vasodilators (not NO, cyclooxygenase prod-
ucts, cGMP, cAMP, or hypoxia-sensitive) mediating arte-
rial dilation,55 regression of established lesions has only
been reported for models with endothelium present. For
example, Zhuang et al studied a rabbit model utilizing
Fig 1. Diagram of temporal changes in the neointima of the
baboon PTFE aorto-iliac graft after the switch to high blood flow.sequential phases of low flow intimal hyperplasia and highflow intimal regression in endothelialized carotid arteries.56
In the baboon PTFE graft model, it is an important obser-
vation that SMCs only proliferate in the area adjacent to the
endothelium,51 suggesting endothelial cell regulation of
SMC function. Although endothelial cell eNOS is in-
creased,50 inhibition of NOS function after the switch to
high flow does not inhibit neointimal regression.51 Other
factors such as hemeoxygenase-1, which catalyses the for-
mation of CO, is induced by high flow after one day (see
online data52), and it may inhibit SMC proliferation via CO
production.57
Tight external wrap-induced medial atrophy. We
have previously reported that rabbit vein grafts adapt to
arterial pressure by increasing total cross-sectional area of
the wall, SMC number, and ECM; this adaptation is sup-
pressed when the grafts are wrapped tightly with PTFE.58 A
rigid perivascular polyethylene cuff around the rabbit aorta
causes medial, but not intimal, atrophy.59 Medial atrophy is
also observed in the carotid artery when another carotid
artery is used as a cuff, thus, proving the foreign body
reaction is not required for medial atrophy.60 We have
recently reproduced these results in baboons; medial, and
not intimal, atrophy in the baboon iliac artery can be
induced in response to a PTFE wrap. This wrap is designed
to limit expansion but not reduce luminal diameter. At 4
days, the tight wrap causes a proportional loss of cells and
ECM, while by 28 days, there is relatively more loss of
ECM61 (unpublished data). In both rabbit and baboon,
the external cuff reduces circumferential strain. Decreased
luminal diameter may also contribute to the atrophy pro-
cess by increasing shear stress.
Neointimal and medial regression in an arterialized
vein graft. Davies et al reported that wall thickening in
vein bypass grafts placed in the arterial circulation of rabbits
for 14 days regresses when the grafts are reimplanted into
the venous circulation. Both intimal and medial areas de-
crease and are associated with apoptosis of SMC and a
relative increase in collagen. These effects are caused by
either a reduction in blood pressure or flow or both.62,63
REGRESSION OF IN-STENT RESTENOSIS
Intimal atrophy occurs spontaneously in stented arter-
ies after about 6 months in humans64,65 and pigs66 and
after about 2 months in rats.67 At these late times, in all
three species,66-68 the neointimal ECM shows a relative
loss of versican and a relative gain of collagen compared
with earlier times. In addition, the data suggest that colla-
gen is more tightly packed or changes from type III to type
I. While human stent neointimas show a loss of SMCs at
times greater than 18 months,68 these late times have not
been studied in animals.
Recently, Hong et al conducted an intravascular ultra-
sound study in humans and at 24 months observed both
regression and progression of lesions first observed at 6
months after bare metal stent implantation.69 While regres-
sion of the intima was observed in 76% of the lesions,
progression was demonstrated in 24%. There is no clue as to
why lesions regress or progress. However, these results
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asymptomatic in-stent restenosis from deliberate interven-
tion to careful observation and reintervention only in se-
lected cases.
While it is clear that the neointima created by stent-
mediated injury undergoes spontaneous regression, there is
a lack of agreement on whether the intima of a traumatized
artery in the absence of a stent undergoes intimal regression
at late times.70,71 One rat carotid injury study observed
regression, and one study did not. In the study in which late
regression was observed,71 there was also a significant de-
crease in lumenal area before regression began. This con-
strictive remodeling might increase shear stress that may in
turn mediate regression. This idea is supported by the
observations of Zhuang et al,56 who studied the effects of
multiple rounds of increasing and decreasing blood flow
through the normal, uninjured rabbit carotid artery by
opening and closing downstream arterio-venous fistulas.
They observed that increased blood flow could cause neo-
intimal regression in this arterial model as was observed in
the baboon PTFE model.
REGRESSION OF CARDIOVASCULAR
HYPERTROPHY IN HYPERTENSION
Cardiovascular hypertrophy and hyperplasia are com-
mon features of hypertension and are important compo-
nents of target organ damage. The regression of cardio-
vascular hypertrophy is now considered an important
therapeutic objective to reduce the complications of hyperten-
sion.72,73 In addition to lowering blood pressure, some anti-
hypertensive drugs, such as losartan, enalapril, and nifedipine,
stimulate SMC apoptosis and reduce DNA synthesis, vascular
mass, and medial cell number in the thoracic aorta of sponta-
neously hypertensive rats (SHR), but not in normotensive
Wistar Kyoto rats (WKY).74 This regression of medial hyper-
trophy in response tomedication is also observed in hyperten-
sive humans.75 In balloon-injured arteries, nifedipine induces
SMC apoptosis in established neointimas in both SHR and
WKY rats and causes lesion regression.76 DeBlois and Hamet
have suggested that induction of SMC apoptosis might be an
important way to reverse the structural changes in the vascu-
lature caused by hypertension.77
Primary pulmonary hypertension is a disorder charac-
terized by hypertensive vasculopathy, vasoconstriction, and
vascular wall remodeling. The histologic findings in idio-
pathic pulmonary hypertension are obliteration of the lu-
men of small- and medium-sized pulmonary arteries in
association with medial hypertrophy, concentric laminar
intimal fibrosis, fibrinoid degeneration, and formation of
plexiform lesions and in situ thrombosis.78 While the patho-
genesis and genetic basis of this disease are poorly understood,
it is nowclear thatmutations in a bonemorphogenetic protein
receptor predispose to both idiopathic and familial forms of
the disease (see review by Said79). Current treatment relies on
various pulmonary vasodilators.
The balance of cell proliferation and apoptosis in pul-
monary artery SMCmaintains the thickness and tissue mass
of the arterial walls at an optimal level. If this balance isdisturbed such that there is more proliferation or less
apoptosis, the arterial wall thickens, narrowing the lumen
and ultimately leading to the obliteration of the vessel and
to an overall increased pulmonary vascular resistance. Pre-
vention or reversal of constrictive vascular remodeling by
inhibiting proliferation and promoting apoptosis in pulmo-
nary artery SMC would be an effective future therapeutic
modality.
In the monocrotaline rat model of pulmonary hyper-
tension, inhibition of either elastase, matrix metallopro-
teinases, or the tyrosine kinase activity of the EGF receptor
reduces expression of the SMC survival factor tenascin C,
increases SMC apoptosis, and causes regression of the
hypertrophied vessel wall by a coordinated loss of cells and
ECM.80-82
The structural changes associated with pulmonary hy-
pertension can be reversed through reducing hemody-
namic stress.83 Of particular interest from the clinical per-
spective are the results of blockade of the tyrosine kinase
activity of the PDGFR receptors by Gleevec (imatinib
mesylate). In both chronic hypoxia and monocrotaline
models in rats and mice, Gleevec reverses the symptoms of
pulmonary hypertension.84 Based on this work, two case
reports showed that Gleevec successfully reverses symp-
toms of idiopathic pulmonary hypertension in patients
refractory to conventional treatments85,86 leading to the
suggestion by Patterson et al that selective PDGFR block-
ade may represent a novel therapy to target vascular remod-
eling in pulmonary arterial hypertension. Because Gleevec
also blocks KIT, LCK, and ABL kinases to the same extent
and others to a lesser degree,87 further work is required to
determine the mechanism of action of this drug.
REGRESSION OF INTIMAL HYPERPLASIA IN
TRANSPLANT ARTERIOPATHY
Transplant vasculopathy is characterized by concentric,
heterogeneous proliferative thickening of the intima of the
allograft vasculature and is initiated and propagated by
both immunological and nonimmunological factors.88,89
The main pathobiologic manifestations of the disease are
the acquisition of an inflammatory endothelial phenotype,
increased SMC proliferation, and defective SMC apoptosis.
Bach et al reported that a number of cytoprotective genes,
including antiapoptotic Bcl family members, Bcl-2 and
Bcl-xL, the heat shock protein heme oxygenase-1, and the
zinc finger protein A20, are expressed in endothelium and
SMCs of long-term surviving cardiac xenografts devoid of
transplant arteriosclerosis.90 These investigators proposed a
cytoprotective recipe that provides the endothelium with
potent anti-inflammatory, anticoagulant, and antiapop-
totic potential and maintains the contractile medial SMC
phenotype.91 While there are reports in animal models
showing that PDGFR blockade by Gleevec prevents the
development of allograft arteriosclerosis in transplanted
hearts,92-94 the definitive role of PDGF in the development
of transplant vasculopathy is still unknown.
It may be possible to induce regression of transplant
vasculopathy. One pharmacologic agent that has shown
 perm
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duced by Streptomyces hygroscopicus. The cellular action
of sirolimus (rapamycin) is mediated by binding to the
FK506 binding protein-12 (FKBP-12).95,96 The resulting
sirolimus/FKBP-12 complex inhibits the kinase activity of
mammalian target of rapamycin (mTOR), subsequently
increasing levels of the cyclin-dependent kinase inhibitor
p27Kip1 96-98 and reducing the activity of multiple kinases
associated with mitogen-induced cell proliferation (eg,
p70s6k, cyclin E/CDK-2). This leads to cell cycle arrest at
the G1/S transition point.96,99-101 Ruygrok et al reported
Fig 2. Histologic cross sections of normal flow PTFE gr
(a), blocking antibodies to PDGFR  (b), blocking antibo
 and  (d). (hemotoxylin-eosin, X16). Intimal areas of
standard error (e). Reproduced from Engelsbe et al93 bya case of angiographic regression of aggressive cardiacallograft vasculopathy after 1 year of sirolimus treatment
started 2 years post-transplantation.102 Park et al reported
regression of transplant coronary artery disease during
chronic low-density lipoprotein-apheresis.103 They found a
7.9% increase of mean luminal diameter due to either
atherosclerotic regression or vessel remodeling.
STRATEGIES TO INDUCE VASCULAR
ATROPHY
The main pathologic features of vessel wall atrophy are
2 weeks after initiation of treatment with vehicle control
to PDGFR  (c), or blocking antibodies to both PDGFR
to seven animals per group are presented as the mean 
ission from Elsevier Publishing.afts at
dies
fourloss of SMCs and ECM resulting from decreased SMC
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lysis. There are several molecular pathways that might be
utilized to induce vascular atrophy.
Platelet-derived growth factors and receptors
(PDGF/ PDGFR). As discussed above, PDGF is a major
regulator of SMC proliferation, migration, and ECM pro-
tein synthesis. Tanizawa et al104 reported PDGF B chain
and PDGFR  receptor were present by immunostaining
and Ueda et al105 found PDGF A and B chain were present
by in situ after PCTA in coronaries. Blockade of PDGFR-
by antibodies inhibits intimal hyperplasia in injured arteries
and PTFE grafts in baboons.28,106 Although by itself it
does not block the induction of intimal thickening,
PDGFR- blockade does cause a decrease in SMC density
and number.106 This latter effect is consistent with the
known survival role of PDGF.107 Of greater interest, how-
ever, is the observation that concomitant antibody block-
ade of PDGFR- and - induces atrophy of established
intima in baboon PTFE grafts under normal flow condi-
tions (Fig 2).108 Simultaneous inhibition of cell prolifera-
tion and stimulation of cell death by the administration of
antibodies to both PDGFR  and  are required to induce
atrophy. While a fully humanized version of the chimeric
antibody to PDGFR- had no effect on restenosis in pa-
tients undergoing coronary stenting,109 it may be that
simultaneous blockade of both receptors is required for an
effect. This goal may be achieved with Gleevec, a PDGFR
kinase inhibitor that appears to reverse pulmonary vascular
hypertrophy and pulmonary hypertension andmight have a
similar effect on intima in vascular reconstructions.
Bonemorphogenic protein 4 (BMP4) and its inhib-
itor noggin. BMPs are members of the transforming
growth factor (TGF)- super family that regulate cell pro-
liferation, migration, differentiation, and apoptosis. High
shear stress induces BMP4 mRNA and protein expression
in the PTFE graft neointima in baboons, while noggin (a
BMP inhibitor) is decreased. BMP4 inhibits SMC prolifer-
ation in vitro, an effect blocked by noggin. Thus, the
increase in BMP4 coupled with a decrease noggin may
contribute to graft neointimal atrophy by inhibiting SMC
proliferation and increasing SMC death.52
A20. A20 is a zinc finger protein induced by tumor
necrosis factor-, interleukin-1, or CD-40 cross-linking in
a variety of cell types.110 A20 prevents intimal hyperplasia
when transfected acutely, but induces regression when
transfected in established intimal lesions of the injured rat
carotid artery.111 Expression of A20 in medial SMC pre-
vents neointima formation by shutting down inflammatory
and proliferative responses of SMC via inhibition of NF-B
and increased expression of the cell cycle dependent kinase
inhibitors p21waf1 and p27kip1. SMCs are also sensitized by
A20 to undergo apoptosis in response to cytokines and
Fas/FasL via a NO-dependent mechanism. This causes
regression of established neointimal lesions. In endothelial
cells, A20 is anti-inflammatory by inhibiting NFB like in
SMCs, but unlike SMC it is antiapoptotic via inhibition of
the proteolytic activation of caspase 8.112 Therefore, A20
has protective effects for endothelial cells and proapoptoticeffects for SMCs making it a good candidate for inducing
vascular atrophy while minimizing endothelial damage.91
Others. Recently, we performed microarray analysis
of our two vascular atrophy models in baboons, namely
the PTFE graft, high flow-induced intimal atrophy model
and the PTFE wrap-induced medial atrophy model. Of
28,000 genes, we found several genes commonly up- or
down-regulated in both models. Upregulated genes in-
cluded extracellular matrix degrading factors and possible
growth regulatory factors. Downregulated genes included
survival factors and matrix genes.113 These molecules may
have important roles in vascular atrophy and may lead to
pharmacological treatments for established lesions.
CONCLUSION
After vascular reconstruction, luminal narrowing is in
part caused by intimal thickening, the consequence of
endothelial injury and inflammation, smooth muscle cell
hyperplasia, and extracellular matrix accumulation. It may
be possible to induce these lesions to shrink (Fig 3). This
novel approach to the treatment of restenosis is supported
by animal experiments and a few clinical observations dem-
onstrating vascular atrophy in response to drugs such as
Gleevec. A potential limitation to this approach might be
the formation of aneurysms. For example, it is known that
venous or arterial aneurysms often form at arterio-venous
fistulas and drug-eluting stents may cause aneurysms.114 It
is clear that a means for targeted delivery of limited dura-
tion would need to be developed. Additional studies are
needed to determine whether this therapy will be broadly
applicable.
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